1357945-49-3Relevant articles and documents
Discovery of a Noncovalent, Mutant-Selective Epidermal Growth Factor Receptor Inhibitor
Chan, Bryan K.,Hanan, Emily J.,Bowman, Krista K.,Bryan, Marian C.,Burdick, Daniel,Chan, Emily,Chen, Yuan,Clausen, Saundra,Dela Vega, Trisha,Dotson, Jennafer,Eigenbrot, Charles,Elliott, Richard L.,Heald, Robert A.,Jackson, Philip S.,Knight, Jamie D.,La, Hank,Lainchbury, Michael D.,Malek, Shiva,Purkey, Hans E.,Schaefer, Gabriele,Schmidt, Stephen,Seward, Eileen M.,Sideris, Steve,Shao, Lily,Wang, Shumei,Yeap, Siew Kuen,Yen, Ivana,Yu, Christine,Heffron, Timothy P.
, p. 9080 - 9093 (2016)
Inhibitors targeting the activating mutants of the epidermal growth factor receptor (EGFR) have found success in the treatment of EGFR mutant positive non-small-cell lung cancer. A secondary point mutation (T790M) in the inhibitor binding site has been li
AZAINDAZOLE COMPOUNDS AS INHIBITORS OF T790M CONTAINING EGFR MUTANTS
-
, (2015/01/16)
This invention relates to novel compounds of formula (I), which are inhibitors of T790M containing EGFR mutants, to pharmaceutical compositions containing them, to processes for their preparation, and to their use in therapy for the prevention or treatment of cancer.